Now, Enveloped positive single stranded RNA-coronavirus is considered the most world concern. The discovery of the new pathogenesis of SARS-COV-2 is requiring us to think out of the box in order to manage this pandemic outrageous virus that has took many lives and still does. Up to this date, 18th of April, 2,256,844 coronavirus confirmed cases and around 154,350 deaths all over countries and territories. General clinical presentation of the infection includes fever, dry cough and shortness of breath and may develop to acute respiratory distress syndrome ARDS, pneumonia, sepsis multi-organ failure, respiratory arrest and eventually causing death. COVID-19 is more likely to affect elderly with comorbidities, requiring ICU admission and mechanical ventilation. Therefore, finding novel treatment approaches is of crucial importance. Disseminated intravascular Coagulation (DIC) is a common complication in hospitalized patients especially ICU patients. Recently, coronavirus was observed to attack heme on the 1-beta chain causing iron-porphyrin dissociation. Heparin pleiotropic effects of anticoagulation and RBC protective effect, makes it a drug of choice in management of COVID-19. It is reported in literature that heparin and heparin like compounds due to polysaccharide component have high inhibitory effects on microbial invasion of red blood cells RBC. The dual benefit of heparin can be of significant importance in COVID-19 and especially for complicated cases and most susceptible individuals.